Overview and Scope
Myocardial infarction is a potentially fatal disorder that develops when the
heart muscle's blood supply is suddenly interrupted, resulting in tissue
damage. Myocardial infarction is triggered by high levels of low-density
lipoprotein in the blood, high blood pressure, and smoking.
Sizing and Forecast
The myocardial infarction market size has grown strongly in recent years. It
will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound
annual growth rate (CAGR) of 7.7%. The growth in the historic period can be
attributed to introduction of beta-blockers, establishment of chest pain
centers, thrombolytic therapies, enomic and personalized medicine approaches,
wearable cardiovascular devices.
The myocardial infarction market size is expected to see strong growth in the
next few years. It will grow to $2.68 billion in 2028 at a compound annual
growth rate (CAGR) of 7.1%. The growth
in the forecast period can be attributed to global health initiatives for
cardiovascular health, expanded access to reperfusion therapies, rna
therapeutics for cardiovascular diseases, patient-centered care models, focus
on microvascular dysfunction, bioelectronic medicine. Major trends in the
forecast period include advancements in cardiovascular imaging, advancements in
cardiac surgery techniques, advancements in telemedicine, integration of
artificial intelligence in diagnosis, innovation of digital biomarkers for risk
prediction, blockchain for healthcare data security, ai-driven drug discovery,
innovations in cardiac rehabilitation technologies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report
Segmentation & Regional Insights
The myocardial infarction market covered in this report is segmented –
1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors,
Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators,
Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers,
Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies
North America was the largest region in the myocardial infarction market in
2023. Europe is expected to be the fastest-growing region in the forecast
period. The regions covered in the myocardial infarction market report are
Asia-Pacific, Western Europe, Eastern Europe, North America, South America,
Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the
report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp
Major Driver Impacting Market Growth
An increasing number of smokers is expected to propel the growth of the
myocardial infarction market going forward. A smoker is anyone who smokes
cigarettes, cigars, or a pipe. Cigarette smoke contains chemicals that cause
the blood to thicken and clot in veins and arteries, and a blockage brought on
by a clot can result in myocardial infarction. For instance, in September 2023,
according to the Office for National Statistics, a UK-based government
department, the segment of the UK population aged 25 to 34 years maintained the
highest percentage of current smokers, accounting for 16.3% or approximately
1.4 million individuals in 2022. This represents an increase from the previous
year, when the same age group had a smoking prevalence of 15.8%, encompassing
around 1.3 million people. Therefore, an increasing number of smokers is
driving the growth of the myocardial infarction market.
Key Industry Players
Major companies operating in the myocardial infarction market report are Pfizer
Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG,
Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott
Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd.,
Bio-Rad Laboratories Inc., Apotex Inc., Siemens Healthcare Diagnostics Limited,
Annexin Pharmaceuticals AB, Dynavax Technologies Corp, Heartseed Inc., Par
Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia
Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys
Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca
Pharmaceuticals AS
The myocardial infarction market report table of contents includes:
1. Executive Summary
2. Myocardial Infarction
Market Characteristics
3. Myocardial Infarction
Market Trends And Strategies
4. Myocardial Infarction
Market - Macro Economic Scenario
5. Global Myocardial
Infarction Market Size and Growth
.
32. Global Myocardial
Infarction Market Competitive Benchmarking
33. Global Myocardial
Infarction Market Competitive Dashboard
34. Key Mergers And
Acquisitions In The Myocardial Infarction Market
35. Myocardial Infarction
Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment